Kehinde Folawewo, MD
Endocrinology, Diabetes & Metabolism · Fredericksburg, VANPI 1710332267
Payments from drug & device makers
Across 85 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$379
- Abbott$192
- IBSA Pharma Inc.$152
- Novo Nordisk$128
- Insulet Corporation$110
- Radius Health, Inc.$107
- plus $779 from 18 others
What the payments were for
- Food & beverage$1,80798%
- Education$392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 18 | $379 |
| Abbott | 9 | $192 |
| IBSA Pharma Inc. | 7 | $152 |
| Novo Nordisk | 6 | $128 |
| Insulet Corporation | 5 | $110 |
| Radius Health, Inc. | 4 | $107 |
| Bayer | 6 | $97 |
| Amgen | 4 | $80 |
| Sanofi-aventis U.S. LLC | 3 | $74 |
| Medtronic | 3 | $64 |
| Boehringer Ingelheim | 3 | $64 |
| AstraZeneca(2 entities) | 3 | $60 |
| Dexcom, Inc. | 2 | $54 |
| Cequr Corporation | 1 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Kerecis Limited | 1 | $27 |
| Averitas Pharma Inc. | 1 | $27 |
| Tandem Diabetes Care, Inc. | 1 | $26 |
| Corcept Therapeutics | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Lifescan, Inc. | 1 | $22 |
| Chiasma, Inc. | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $20 |
How this compares
$1,846 in reported general payments places this provider in the 55th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 116 | $236,104 |
| TrulicityDulaglutide | 91 | $162,884 |
| MounjaroTirzepatide | 65 | $132,796 |
| JardianceEmpagliflozin | 78 | $109,014 |
| FarxigaDapagliflozin Propanediol | 43 | $59,907 |
| JanuviaSitagliptin Phosphate | 49 | $47,479 |
| RybelsusSemaglutide | 18 | $37,571 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $20,522 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 120 | $20,231 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $18,682 |
| Novolog FlexpenInsulin Aspart | 38 | $17,081 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 51 | $14,172 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 84 | $9,557 |
| Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm | 15 | $8,014 |
| Humulin N KwikpenInsulin Nph Human Isophane | 11 | $4,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $379 | $295,680156 claims |
| Novo NordiskOzempic, Rybelsus | $128 | $273,675134 claims |
| Boehringer IngelheimJardiance | $64 | $109,01478 claims |
| AstraZenecaFarxiga | $60 | $59,90743 claims |
| Sanofi-aventis U.S. LLCLantus | $74 | $2,27111 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $1,923155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Fredericksburg
- Reshma ParabFredericksburg$6K
- Domenica RubinoArlington$3M
- Suzanne Jan de BeurCharlottesville$1.5M
- Farhad ZangenehSterling$1.2M
- Ali IranmaneshSalem$1.1M
- Elias SirajNorfolk$884K
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- James la RocqueChesapeake$576K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.